louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01781832: Bladder ARFI (Acoustic Radiation Force Impulse) Study
Official title: Evaluation of Pediatric Urinary Bladder Wall Thickening and Fibrosis Using Acoustic Radiation Force Impulse (ARFI)-Derived Shear Wave Velocities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bladder Fibrosis
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2013-02-01
Enrollment: 26
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Urinary bladder fibrosis (thickening and scarring) is fairly uncommon in children. Traditionally, the presence of urinary bladder fibrosis has been confirmed directly with bladder biopsy or using urodynamic testing. In this study we will use ultrasound scanning and ARFI (acoustic radiation force impulse) wave velocities to potentially identify any urinary bladder wall fibrosis.

Detailed description: Urinary bladder fibrosis (thickening and scarring) is fairly uncommon in children. Traditionally, the presence of urinary bladder fibrosis has been confirmed directly with bladder biopsy or using urodynamic testing.

We will use ultrasound ARFI (acoustic radiation force impulse)-derived shear wave velocities to potentially identify the presence of urinary bladder wall fibrosis. We hypothesize that shear wave velocities found within the bladder wall will increase with increasing evidence of fibrosis.

Eligibility criteria: Inclusion Criteria:

1. 18 years of age or younger
2. Have an order for urodynamic testing from your doctor

Exclusion Criteria:

1. Adults
2. Unwilling to sign consent form

Primary outcomes:
measure: Shear Wave Velocity, VTQ
timeFrame: Visit 0
measure: Shear Wave Velocity (VITQ)
timeFrame: Visit 0
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Hospital
state: Michigan
Study officials:
affiliation: University of Michigan Hospital
name: Ethan Smith, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04792632: Clinical Performance Evaluation of Veye Lung Nodules
Official title: Clinical Performance Evaluation of Veye Lung Nodules
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lung; Node
Lead sponsor: Aidence
Sponsor class: INDUSTRY
First posted: 2021-03-11
Enrollment: 350
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CROSSOVER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: US adult population that received a CT chest scan either as part of a lung cancer screening program or during routine practice

Brief summary: Veye Lung Nodules (Aidence B.V., Amsterdam, the Netherlands) is a medical software device that is intended to assist radiologists with pulmonary nodule management on CT chest scans.

This clinical trial aims to assess the clinical performance of Veye Lung nodules via a standalone performance evaluation and a reader study.


Eligibility criteria: Inclusion Criteria:

- Subjects that underwent a CT chest scan for either lung cancer screening or routine practice

Exclusion Criteria:

* Subjects with \>10 pulmonary nodules;
* Subjects with pulmonary mass(es) = largest axial diameter \>30mm;
* Subjects with interstitial lung disease.

Primary outcomes:
measure: Detection accuracy
timeFrame: 2 months
Secondary outcomes:
measure: Segmentation accuracy
timeFrame: 1 month
Other outcomes:
measure: Growth assessment accuracy
timeFrame: 1 month
measure: Composition classification accuracy
timeFrame: 2 months
Locations:
city: Boston
country: United States
facility: Intrinsic Imaging
state: Massachusetts
Study officials:
References:
Clinical trial NCT03714932: Accuracy of Arch Analysis in Mixed Dentition Using Digital Models Versus Plaster Ones.
Official title: Accuracy of Arch Analysis in Mixed Dentition Using Digital Study Models Versus the Plaster Models Using Tanaka and Johnston Prediction Equation:
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Dental Malocclusion
Keywords: Arch analysis, Mixed dentition,Tanaka & Johnston
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-10-22
Enrollment: 10
Sex: ALL
Minimum age (years): 6
Maximum age (years): 10
Standard ages: CHILD
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children aged six to Ten years.

Brief summary: Accuracy of arch analysis in mixed dentition using digital study models versus the plaster models using Tanaka and Johnston prediction equation:

Detailed description: Space analysis is traditionally performed by diagnostic measurements that have been obtained from plaster dental casts through measurements which might be influenced by subjective interpretation and bias when constructed.

\*So another method of diagnostically measuring study models was introduced (Digital software). This system creates digital images of dental casts with software. From the digitized models, various analyses and routine measurements could be done that might accelerate and solve many problems and difficulties associated with storage, retrieval, reproduction, communication, and breakage of conventional plaster casts.

* Taking an impressions for a mixed dentition aged children.
* Perform a measurements using Tanaka and Johnston equation for an arch analysis using a caliper and 3Shape ortho-analyzer software.
* Casts will be scanned using the 3D scanner then by using the 3shape software measurements will be held according to Tanaka and Johnstopn prediction equation.

Eligibility criteria: Inclusion Criteria:

* Aged range from 6-10.
* patients medically free from any syndromes that could affect the normal eruption.
* Normal radiographical findings in teeth eruption.
* Erupted lower incisors.

Exclusion Criteria:

* Extracted lower 1st permanent molar.
* congenital missing of incisors.
* Badly decayed permanent incisors or 1st molar that could compromise the measurements.
* Any sensitivity to any of the impression materials.

Primary outcomes:
measure: accuracy of digital models in arch analysis.
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: sara Mohamed
Study officials:
affiliation: Cairo University
name: sara Mohamed Tag El Deen, Master
role: STUDY_DIRECTOR
References:
Clinical trial NCT05858632: Immune Spatial Features of Guselkumab Cutaneous Response
Official title: Immune Spatial Features of Guselkumab Cutaneous Response
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Psoriasis of Scalp
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: Janssen Scientific Affairs, LLC
First posted: 2023-05-15
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

Detailed description: This is a one-arm, open-label study to examine the effect of Guselkumab . Guselkumab is a FDA-approved medication for the treatment of psoriasis. This study will examine how Guselkumab affects immune cells within scalp psoriasis lesions. Ten subjects with moderate to severe scalp psoriasis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with Guselkumab treatment response.

Eligibility criteria: Inclusion Criteria: possess a PSSI (psoriasis scalp severity index) of ≥12

Exclusion Criteria:

1. taking systemic immunosuppressives in the last 4 weeks
2. pregnancy
3. severe immunodeficiency (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
8. Males who are trying to conceive

   -

Primary outcomes:
measure: Change in psoriasis scalp severity index score (PSSI)
timeFrame: baseline and 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California San Francisco
state: California
Study officials:
affiliation: University of California, San Francisco
name: Raymond Cho, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01800032: PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
Official title: Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography- Magnetic Resonance Imaging (FDG-PET-MRI) in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neurofibromatosis-1
Optic Glioma
Plexiform Neurofibroma
Lead sponsor: UNC Lineberger Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2013-02-27
Enrollment: 30
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: UNC Hospitals

Brief summary: This prospective pilot study is designed to provide preliminary data on the use of Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) in patients with neurofibromatosis-1 (NF1) associated optic glioma and plexiform neurofibroma (PN).

Subjects will undergo FDG-PET-MRI scans in place of standard of care imaging at 0 and 12 months, unless more frequent imaging is clinically indicated. Subjects and their family caregivers will also undergo serial interviews and complete questionnaires related to the psychosocial aspects of NF1.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with neurofibromatosis-1 with either optic glioma, due for imaging scan, or plexiform neurofibroma, due for imaging secondary to clinical signs or symptoms of progressive disease
* ≥ 6 years of age
* English-speaking
* If female of child-bearing potential, negative urine pregnancy test performed within 7 days prior to each FDG-PET-MRI
* Study-specific informed consent or assent obtained and signed

Exclusion Criteria:

* Unable to undergo FDG-PET-MRI without sedation
* Currently undergoing chemotherapy for progressing optic glioma
* Pregnant or lactating female
* Poorly controlled diabetes mellitus
* Presence of pacemaker, intracranial aneurysm clip, cochlear implant, metal halo device, epicardial pacemaker leads, or any other device that makes MRI unsafe
* Serum creatinine \> 1.8 mg/dL OR GFR \< 30 mL/min
* Unable to lie flat for \> 1 hour
* Body Mass Index (BMI) \> 35

Primary outcomes:
measure: Plexiform Neurofibroma Cohort: Difference in FDG-avidity between progressive and non-progressive lesions
timeFrame: 12 months
measure: Optic Glioma Patients: Compare FDG-avidity between patients with progressive and non-progressive disease
timeFrame: 12 months
Secondary outcomes:
measure: Report descriptive statistics for FDG-PET-MRI results
timeFrame: 0, 12 months
measure: Explore impact of FDG-PET-MRI surveillance on patient and family caregiver uncertainty and psychological distress
timeFrame: 0, 12 months
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: University of North Carolina-Chapel Hill
state: North Carolina
Study officials:
affiliation: University of North Carolina, Chapel Hill
name: Timothy Gershon, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06847932: Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development
Official title: Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development: a Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Atrial Fibrillation (AF)
Premature Atrial Complexes
Atrial Arrhythmias
Artificial Intelligence (AI)
Electrocardiogram
Lead sponsor: National Defense Medical Center, Taiwan
Sponsor class: OTHER
First posted: 2025-02-26
Enrollment: 14726
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Our study aimed to use an AF-predict AI-ECG alert system to help physicians identify patients who need to wear a continuous cardiac rhythm monitor for new diagnoses of atrial fibrillation (AF), atrial flutter (AFL), or atrial arrhythmia with high AF risk, including premature atrial complexes (PAC) ≥ 500/24hr, burst PACs \> 20 beats, non-sustained AF/AFL.


Eligibility criteria: Inclusion Criteria:

* Patients in the inpatient department or the outpatient department
* Patients need to have at least one electrocardiogram within one year

Exclusion Criteria:

* Diagnosis of atrial fibrillation/atrial flutter
* History of atrial fibrillation/atrial flutter catheter ablation
* Patients with cardiac implantable electronic devices
* Any documented electrocardiogram showed atrial fibrillation/atrial flutter and pacing rhythm
* History of received rhythm control medications for atrial arrhythmia, including Class I and Class III antiarrhythmic drugs
* Any reasons indicate for anti-coagulant agents, including vitamin K antagonist and non-vitamin K antagonist oral anticoagulant

Primary outcomes:
measure: Latent atrial fibrillation
timeFrame: Within 90 days after enrollment.
Secondary outcomes:
measure: Antiarrhythmic treatment
timeFrame: Within 180 days after enrollment.
measure: 90-days New diagnoses of atrial fibrillation/atrial flutter
timeFrame: Within 90 days after enrollment.
measure: Atrial arrhythmia with high AF risk
timeFrame: Within 90 days after enrollment.
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Tri-Service General Hospital
Study officials:
affiliation: National Defense Medical Center
name: Chin Lin, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00178932: Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
Official title: Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Schizophrenia
Schizoaffective Disorder
Bipolar Disorder
Major Depression
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2005-09-15
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.


Eligibility criteria: Inclusion Criteria:

Patients with the diagnoses of schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features, or volunteers with no history of a psychotic disorder.

Exclusion Criteria:

Patients with DSM-IV diagnoses other than schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features.

Primary outcomes:
measure: We plan to compare the polymorphisms across schizophrenic patients and adults who do not have a diagnosed major mental illness. .
timeFrame: single visit
Secondary outcomes:
measure: We will also evaluate relationships between the polymorphism and past and current mental health among the non-diagnosed sample
timeFrame: single visit
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Psychiatric Hospital at Vanderbilt
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: Herbert Y Meltzer, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00502632: Dornase Alfa and Urokinase for Kids With Pleural Empyema
Official title: Multicentre Randomized Double-Blinded Trial of Intrapleural Dornase Alfa and Urokinase vs Urokinase Alone for Complicated Parapneumonic Effusions in Children
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Pleural Empyema
Keywords: Pleural empyema
Pleural effusion
Dornase alfa
Urokinase
Children
Lead sponsor: Azienda Ospedaliera di Padova
Sponsor class: OTHER
Collaborators: name: Hoffmann-La Roche
First posted: 2007-07-17
Enrollment: 94
Sex: ALL
Minimum age (years): 1
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether intrapleural treatment with Dornase alfa plus Urokinase improves clinical outcome compared to Urokinase alone in children with complicated parapneumonic effusions


Eligibility criteria: Inclusion Criteria:

* Age \> 1 year and \< 16 years
* Respiratory infection (pneumonia or lung abscess)
* Effusion occupying at least 1/3 of hemithorax on chest X-ray
* Complicated effusion (presence of at least one of the following):

  * Hyperechoic pleural fluid on chest US scan
  * Loculated collection on chest US or CT scan
  * Purulent pleural fluid
  * Positive culture or Gram stain on pleural fluid

Exclusion Criteria:

* Non parapneumonic effusion
* Immunodeficiency
* Neurological impairment
* Suspected or proven allergy to Urokinase or Dornase alfa
* Suspected or documented bronchopleural fistula
* Impaired coagulation (INR\>2), haemorrhage, high risk for bleeding
* Thoracic surgical procedure (e.g. thoracoscopy, mini-thoracotomy) already performed
* Chest drain inserted since 6 or more days

Primary outcomes:
measure: Duration of hospital stay
timeFrame: From beginning of intrapleural treatment
measure: Need for additional surgical procedures
timeFrame: 3 months
Secondary outcomes:
measure: Duration of suction applied to chest drain
timeFrame: From beginning of intrapleural treatment
measure: Duration of fever
timeFrame: From beginning of intrapleural treatment
measure: Duration of intravenous antibiotic treatment
timeFrame: From beginning of intrapleural treatment
Other outcomes:
Locations:
city: Bergamo
country: Italy
facility: Ospedali Riuniti di Bergamo
city: Padova
country: Italy
facility: Azienda Ospedaliera di Padova
city: Roma
country: Italy
facility: Ospedale Bambino Gesu'
Study officials:
affiliation: Azienda Ospedaliera di Padova
name: PierGiorgio Gamba, MD
role: STUDY_CHAIR
affiliation: Women's and Children's Hospital, Adelaide, SA
name: Giorgio Stefanutti, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00514332: Comparison Between Colorectal Stents and Primary Surgery in Obstructive Colonic Cancer. A Randomized, Controlled Study
Official title: Etude Prospective Multicentrique randomisée Comparant Deux stratégies thérapeutiques Pour Les Cancers Coliques en Occlusion : stratégie Chirurgicale Exclusive Versus stratégie thérapeutique Avec Stent Colique Initial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Colorectal Obstruction
Left Colonic Adenocarcinoma
Keywords: colorectal stents
colonic obstruction
colonic adenocarcinoma
colorectal surgery
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
Collaborators: name: University Hospital, Rouen
name: University Hospital, Toulouse
name: University Hospital, Grenoble
name: Rennes University Hospital
name: University Hospital, Lille
name: University Hospital, Angers
name: University Hospital, Bordeaux
First posted: 2007-08-09
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate wether colorectal stenting carry a significant clinical advantage

Detailed description: Randomized controlled comparison between stents and primary surgery in obstructive left colonic obstructive carcinoma outside palliative situations.

Eligibility criteria: Inclusion Criteria:

* obstructive stenosis due to left colorectal cancer

Exclusion Criteria:

* previous colorectal cancer
* other colorectal location

Primary outcomes:
measure: number of stoma in each group
timeFrame: within the first 6 month(plus or minus 1 month) after surgery
Secondary outcomes:
measure: mortality in each group
timeFrame: within the first 6 month (plus or minus 1 month) after surgery
measure: complications
timeFrame: within the first 6 month (plus or minus 1 month) after surgery
measure: number of procedures
timeFrame: within the first 6 month (plus or minus 1 month) after surgery
measure: length of stay
timeFrame: within the first 6 month (plus or minus 1 month) after surgery
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital, Montpellier
name: Bertrand L MILLAT, MD-PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Pirlet IA, Slim K, Kwiatkowski F, Michot F, Millat BL. Emergency preoperative stenting versus surgery for acute left-sided malignant colonic obstruction: a multicenter randomized controlled trial. Surg Endosc. 2011 Jun;25(6):1814-21. doi: 10.1007/s00464-010-1471-6. Epub 2010 Dec 18.